Skip to main content
Premium Trial:

Request an Annual Quote

Bit of Cash

According to FierceBiotech, Jonathan Rothberg's LAM Therapeutics has raised some $40 million to power its development of treatments for cancer and rare diseases.

In a statement, the company says that it combines next-generation sequencing, genome-editing methods, computer science, and artificial intelligence to uncover and develop therapeutics faster, cheaper, and more precisely than other approaches.

It, FierceBiotech adds, is embarking on a Phase I trial of an inhalable mTOR inhibitor treatment for the rare and often fatal lung disease lymphangioleiomyomatosis as well as a Phase I trial of a kinase inhibitor to treat refractory non-Hodgkin lymphoma.

"We built LAM Therapeutics from the ground up to transform the way we develop medicines," Rothberg says in a statement. "We are at an inflection point: DNA sequencing and computer science have both advanced over a million fold since our first attempts to create true genomics-based medicines."

LAM Therapeutics came out of Rothberg's startup incubator 4Catalyzer.